UONEK Earnings

UONEK reported its earnings on 2024-06-07, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was -0.15, surpassing the expected 0 by 0% . The stock experienced a -1.24% price change on the earnings day and a -7.45% change over the next five days, reflecting market reactions to the results.

Following UONEK's earnings announcement on 2024-06-07, the stock price moved by -1.24% on the day of the release. Over the subsequent five days, it saw a -7.45% change. Historically, UONEK's stock price tends to shift by an average of -1.89% in the 10 days leading up to earnings and -1.26% in the 10 days following, providing insight into potential market.

For , analysts estimate UONEK’s annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue Go Up by 81.96% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between UONEK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for were Go Up by 81.96%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, UONEK's stock price typically moves by -1.89% in the 10 days before its earnings and -1.26% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

The earnings report shows declining revenues across most segments, a significant drop in adjusted EBITDA, and a net loss in Q4 2023. While there is an improvement in Q1 2024 net income, the overall financial health is concerning with increased operating expenses and a lack of clear strategy for reversing negative trends in digital and Reach segments. The Q&A section reveals management's uncertainty in addressing these issues, and the expected softness in Q2 further dampens the outlook. Without a clear recovery plan, the stock is likely to face negative pressure.